| Literature DB >> 33583200 |
Antonia Vlahou1, Dara Hallinan2, Rolf Apweiler3, Angel Argiles4, Joachim Beige5, Ariela Benigni6, Rainer Bischoff7, Peter C Black8, Franziska Boehm2, Jocelyn Céraline9, George P Chrousos10, Christian Delles11, Pieter Evenepoel12, Ivo Fridolin13, Griet Glorieux14, Alain J van Gool15, Isabel Heidegger16, John P A Ioannidis17, Joachim Jankowski18, Vera Jankowski18, Carmen Jeronimo19, Ashish M Kamat20, Rosalinde Masereeuw21, Gert Mayer22, Harald Mischak23, Alberto Ortiz24, Giuseppe Remuzzi6, Peter Rossing25, Joost P Schanstra26, Bernd J Schmitz-Dräger27, Goce Spasovski28, Jan A Staessen29, Dimitrios Stamatialis30, Peter Stenvinkel31, Christoph Wanner32, Stephen B Williams33, Faiez Zannad34, Carmine Zoccali35, Raymond Vanholder36.
Abstract
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.Entities:
Keywords: Ethics, Research; Government Regulation; biomedical research; data management; informed consent
Year: 2021 PMID: 33583200 PMCID: PMC7968961 DOI: 10.1161/HYPERTENSIONAHA.120.16340
Source DB: PubMed Journal: Hypertension ISSN: 0194-911X Impact factor: 10.190